126924-38-7

Basic information

• Product Name: (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE
• Synonyms: (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE;Seproxetine [inn];Unii-25co3X0R31;(S)-Norfluoxetine
• CAS NO: 126924-38-7
• Molecular Formula: C₁₆H₁₆F₃NO
• Molecular Weight: 295.2995496
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Isotope Labelled Compounds;Metabolites & Impurities;Pharmaceuticals;Amines
• Mol File: 126924-38-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 381.1°C at 760 mmHg
• Flash Point: 184.3°C
• Appearance: /
• Density: 1.204g/cm³
• Vapor Pressure: 5.21E-06mmHg at 25°C
• Refractive Index: 1.525
• Storage Temp.: Hygroscopic, -20?C Freezer, Under Inert Atmosphere
• CAS DataBase Reference: (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE(126924-38-7)
• EPA Substance Registry System: (S)-3-PHENYL-3-(4-TRIFLUOROMETHYL-PHENOXY)-PROPYLAMINE(126924-38-7)

Safety Data

• Hazardous Substances Data: 126924-38-7(Hazardous Substances Data)

Usage

Chemical Properties

Pale Yellow Oil

Uses

Different sources of media describe the Uses of 126924-38-7 differently. You can refer to the following data:
1. A metabolite of Fluoxetine (F597100), a selective serotonin reuptake inhibitor which is used as an antidepressant.
2. (S)-Norfluoxetine is a labelled Fluoxetine (F597100) derivative,it is a stereoselective inhibitorof serotonin re-uptake and phosphodiesterase. It is used as a potential antidepressants.
3. A labelled metabolite of Fluoxetine, a selective serotonin reuptake inhibitor which is used as an antidepressant.
4. A metabolite of Fluoxetine, a selective serotonin reuptake inhibitor which is used as an antidepressant.

InChI:InChI=1/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m0/s1

Upstream product

• 402-44-8 4-Fluorobenzotrifluoride 
• 130194-42-2 (1S)-3-amino-1-phenyl-1-propanol 
• 100568-02-3 (S)-fluoxetine 
• 114133-37-8 (S)-N-methyl-3-amino-1-phenyl-1-propanol 
• 114446-51-4 -(-)-1-chloro-3-phenyl-3-<4-(trifluoromethyl)phenoxy>propane 
• 100306-33-0 (1R)-3-chloro-1-phenylpropanol 
• 878663-13-9 (S)-1-phthalimido-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane 
• 83891-03-6 norfluoxetine 
• 20780-53-4 (R)-Styrene oxide 
• 191729-82-5 (R)-Phenyl-(4-trifluoromethyl-phenoxy)-acetic acid (S)-1-methyl-2-oxo-2-pyrrolidin-1-yl-ethyl ester 
• 191729-85-8 (R)-2-Phenyl-2-(4-trifluoromethyl-phenoxy)-ethanol 
• 402-45-9 4-hydroxybenzotrifluoride 
• 132203-26-0 (S)-3-hydroxy-3-phenylpropanenitrile 
• 191729-88-1 (S)-3-Phenyl-3-(4-trifluoromethyl-phenoxy)-propionitrile 

Downstream Products

• 878663-14-0 C₃₇H₄₂F₃N₃O₄ 
• 878663-16-2 N'-(R)-[1-(1-naphthyl)ethyl]-N-(S)-3-[4-(triflouromethyl)phenoxy]-3-phenylpropylurea 
• 114247-06-2 (S)-fluoxetine hydrochloride 

Relevant articles and documents

Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: Opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (S)-fluoxetine, and N-desmethyldiltiazem

Three secondary amines desipramine (DES), (S)-fluoxetine [(S)-FLX], and N-desmethyldiltiazem (MA) undergo N-hydroxylation to the corresponding secondary hydroxylamines [N-hydroxydesipramine, (S)-N-hydroxyfluoxetine, and N-hydroxy-N-desmethyldiltiazem] by cytochromes P450 2C11, 2C19, and 3A4, respectively. The expected primary amine products, N-desmethyldesipramine, (S)-norfluoxetine, and N,N-didesmethyldiltiazem, are also observed. The formation of metabolic-intermediate (MI) complexes from these substrates and metabolites was examined. In each example, the initial rates of MI complex accumulation followed the order secondary hydroxylamine > secondary amine ? primary amine, suggesting that the primary amine metabolites do not contribute to formation of MI complexes from these secondary amines. Furthermore, the primary amine metabolites, which accumulate in incubations of the secondary amines, inhibit MI complex formation. Mass balance studies provided estimates of the product ratios of N-dealkylation to N-hydroxylation. The ratios were 2.9 (DES-CYP2C11), 3.6 [(S)-FLX-CYP2C19], and 0.8 (MA-CYP3A4), indicating that secondary hydroxylamines are significant metabolites of the P450-mediated metabolism of secondary alkyl amines. Parallel studies with N-methyl-d3-desipramine and CYP2C11 demonstrated significant isotopically sensitive switching from N-demethylation to N-hydroxylation. These findings demonstrate that the major pathway to MI complex formation from these secondary amines arises from N-hydroxylation rather than N-dealkylation and that the primary amines are significant competitive inhibitors of MI complex formation. Copyright

MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS

Disclosed are agents having pharmacological activity against cellular receptors and intracellular singaling, particularly receptors and sigaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents.

Stereoselective synthesis of 2-Aryloxy esters: An asymmetric approach to fluoxetine, tomoxetine and nisoxetine

-